Portia Smallbone, MBBS (Hons)

Peer-Reviewed Articles

1. Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
2. Lambert N, Forte F, El Moussaoui M, Monseur J, Raus N, Polushin A, Michonneau D, Shultz C, Hogan WJ, Balaguer-Rosello A, Gil-Perotin S, Brijs J, Chauvet P, Gavriilaki M, Carre M, Dulamea AO, Chalandon Y, Salmenniemi U, Duminuco A, Ram R, Garcia-Cadenas I, Porto G, Nguyen S, Smallbone P, Gonzalez-Vicent M, Santoro JD, Willems E, Baron F, Servais S, Beguin Y, Maquet P. Central nervous system manifestations in acute and chronic graft-versus-host disease. Brain, 2024. e-Pub 2024. PMID: 39442000.
3. Di Ciaccio PR, Mills G, Shipton MJ, Campbell B, Gregory G, Langfield J, Greenwood M, McKeague S, Shanavas M, Eslick R, Kidson-Gerber G, Smallbone P, Tang C, Morris K, Bilmon I, Yannakou CK, Badoux X, Berkahn L, Farina S, Mason KD, Motum P, Goss K, Hamad N. The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance. Br J Haematol 201(5):887-896, 2023. e-Pub 2023. PMID: 36880558.
4. Fysh ETH, Smallbone P, Mattock N, McCloskey C, Litton E, Wibrow B, Ho KM, Lee YCG. Clinically Significant Pleural Effusion in Intensive Care: A Prospective Multicenter Cohort Study. Crit Care Explor 2(1):e0070, 2020. e-Pub 2020. PMID: 32166290.
5. Kuzich JA, Hutchison AP, Lim KJC, Smallbone P, Denning K, Wright MP, Cull G, Leahy MF, Joske DJL, Radeski D, Purtill D. Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia. Leuk Lymphoma 60(14):3417-3425, 2019. e-Pub 2019. PMID: 31304820.

Other Articles

1. Smallbone P, Louw A, Purtill D Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis. Pathology 56(1):24-32, 2024. PMID: 38071159.
2. Lambert N, Forte F, El Moussaoui M, Monseur J, Raus N, Polushin A, Michonneau D, Schultz C, Smallbone P, Maquet P Central nervous system manifestations in acute and chronic graft-versus-host disease. Lancet Haematology.
3. Alousi A, Marcoux C, Im J, Hill L, Smallbone P, Mehta R Gastrointestinal Involvement Refines Prognosis in Minnesota Standard Risk Acute Graft-vs-Host Disease. Bone Marrow Transplantation.
4. Smallbone P, Amanuel B, Robbins PD, Passage J, Grove CS EBV-associated diffuse large B cell lymphoma arising within atrial myxoma in an immunocompetent patient can be treated successfully with surgery alone. Pathology 52(3):379-382, 2020. PMID: 32107076.

Abstracts

1. Fysh E, Smallbone P, Mccloskey C, Roberts B, Litton E, Ho KM, Wibrow B, Lee YCG. Pleural Research In Intensive Care (PRINCE-1) A Prospective Observational Study Of Pleural Effusion Management. Respirology 22:60-61, 2017. e-Pub 2017.
2. Smallbone P, Robbins P, Kuok Y, Purtill D. Ruxolitinib use in chronic graft-versus-host disease affecting the central nervous system: a case report. Blood - Haematology Society of Australia and New Zealand Annual Scientific Meeting.
3. Smallbone P, Copeland T, Lombard M, Cooney J, Cannell P, Wright M, Purtill D. Haemorrhagic cystitis post allogeneic stem cell transplant: a review of recent outcomes at a single centre. Blood - Haematology Society of Australia and New Zealand Annual Scientific Meeting.
4. Lombard M, Smallbone P, Cooney J, Cannell P, Wright M, Purtill D, Lam S. Viral morbidity in allogeneic stem cell transplant recipients receiving ATG for GvHD prophylaxis. Blood (Haematology Society of Australia and New Zealand) Annual Scientific Meeting.
5. Smallbone P, Shpall EJ, Champlin R, Qazilbash M, Srour S. Impact of hematopoietic cell transplantation comorbidity index (HCT-CI) on AL Amyloidosis outcomes. TANDEM 2024.
6. Smallbone P, Sekhar M, Srour S, Shpall EJ, Popat U. Hematopoietic stem cell transplantation in patients with myelofibrosis and splanchnic vein thrombosis. TANDEM 2024.
7. Smallbone P, Oran B, Popat U, Champlin R, Shpall EJ. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. European Hematology Association (EHA).
8. Smallbone P, Champlin R, Shpall EJ, Oran B. HLA-DPB1 mismatches and the impact on unrelated donor transplant outcomes with the use of post-transplant cyclophosphamide. American Society of Hematology (ASH).
9. Smallbone P, Cao K, Saliba RM, Alvarez M, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Ramdial JL, Champlin RE, Shpall EJ, Oran B. HLA-DBP1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide. TANDEM Meetings of ASTCT and CIBMTR 2025.
10. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. TANDEM Meetings of ASTCT and CIBMTR 2025.
11. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. TANDEM Meetings of ASTCT and CIBMTR 2025.
12. Aljawai YM, Smallbone P, Alousi AM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Kebriaei P, Marin D, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. TANDEM Meetings of ASTCT and CIBMTR 2025.
13. Hosing C M, Saliba R M, Alousi A M, Alatrash G, Aljawai Y M, Bashir Q, Chen G L, Fingrut W B, Im J S, Kebriaei P, Marin D, Nieto Y, Olson A L, Oran B, Qazilbash M H, Ramdial J L, Saini N Y, Smallbone P, Srour S A, Bazinet A, GarciaManero G, Champlin R E, Andersson B S, Shpall E J, Popat U R. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. TANDEM Meetings of ASTCT and CIBMTR 2025.
14. Cervoni-Curet FN, Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ, Fingrut WB. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. TANDEM Meetings of ASTCT and CIBMTR 2025.
15. Srour SA, Saliba RM, Ramdial JL, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen GL, Qazilbash MH, Kebriaei P, Hosing CM, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat UR. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. TANDEM Meetings of ASTCT and CIBMTR 2025.

Letters to the Editor

1. Smallbone, PI, Sekhar, M, Srour, S, Ramdial, JL, Carmicheal Kusy, CL, Shpall, E, Popat, UR. Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis. Am J Hematol 100: 305-309, 2025.